FFF Enterprises: BioSupply Trends Newsletter
Tuesday, Apr 18, 2017

New Rotavirus Vaccine Is More Protective in Children

 

In this Issue

•  Superbug Apocalypse:
A Post-Antibiotic Era?
•  Quality Improvement Programs:
Hurdles to Optimizing Care
•  Autism: Preparing for Aging Out of the System
•  Update on Zika Virus
•  Myths and Facts: Obesity
     
   
     
 

A new vaccine to protect against rotavirus, a deadly diarrheal disease that kills approximately 450,000 children younger than 5 years old each year, has been developed by Serum Institute of India. [ read more ]

Pertussis Vaccine in Pregnancy Protects Nine of 10 Newborns from Whopping Cough

A new study shows newborns of pregnant women who have gotten their pertussis booster vaccine are far less likely to get the disease than other babies. [ read more ]

CDC Study Shows Flu Vaccine Reduces Risk of Death in Children

A new study conducted by the Centers for Disease Control and Prevention (CDC) shows that during the years 2010 through 2014, the influenza vaccine reduced the risk of flu-associated death by half among children with underlying high-risk medical conditions and by nearly two-thirds among healthy children. [ read more ]

Industry News

 
 

From Octapharma USA

Octapharma USA has awarded an educational grant to the Global Blood Disorder Foundation to sponsor the first national conference for patients with type 3 von Willebrand disease. The event, “Making the Connection,” will be held May 12-15.
[ read more ]

From American Autoimmune Related Diseases Association

A survey conducted by the American Autoimmune Related Diseases Association has found that the vast majority of autoimmune disease patients do not believe that U.S. federal and state elected officials understand that autoimmunity is a major U.S. health issue.  [ read more ]

From Genentech

The U.S. Food and Drug Administration has approved Genentech’s ocrelizumab (Ocrevus), which is the first to have an effect on primary progressive multiple sclerosis (MS), the most severe form of MS, by targeting the body’s B cells. [ read more ]

IVIG & Albumin Supply Index

 
 

What's New at FFF

Bivalirudin (Fresenius Kabi)

Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients 1) with unstable angina undergoing percutaneous transluminal coronary angioplasty; 2) undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor as in the REPLACE-2 study; and 3) with, or at risk of, heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome, undergoing PCI. It is available for intravenous use, and is supplied in a single-use vial containing 250 mg of Bivalirudin. It is intended for use with aspirin, and has been studied only in patients receiving concomitant aspirin.

For more information about Bivalirudin, login to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective April 1, 2017, through June 30, 2017.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $65.28 $64.23
Flebogamma J1572 $60.35 $59.38
Gammagard S/D J1566 $65.28 $64.23
Gammaplex J1557 $83.23 $81.90
Octagam J1568 $72.17 $71.02
Privigen J1459 $77.73 $76.49
SCIG
Cuvitru J3490 / J3590 / J7799 ** **
Hizentra J1559 $98.26 $96.68
HyQvia J1575 $129.56 $127.48
IVIG / SCIG
Gammagard Liquid J1569 $80.86 $79.57
Gammaked J1561 $67.86 $66.77
Gamunex-C J1561 $67.86 $66.77

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** Cuvitru does not yet have Medicare rates.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2017 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.